Diabetes in pregnancy and epigenetic mechanisms

how the first 9 months from conception might affect the child's epigenome and later risk of disease

Line Hjort, Boris Novakovic , Louise G Grunnet , Louise Maple-Brown, Peter Damm, Gernot Desoye, Richard Saffery

    Research output: Contribution to journalReview articleResearchpeer-review

    Abstract

    Diabetes in pregnancy is not only associated with increased risk of pregnancy complications and subsequent maternal metabolic disease, but also increases the risk of long-term metabolic disease in the offspring. At the interface between genetic and environmental factors, epigenetic variation established in utero represents a plausible link between the in utero environment and later disease susceptibility. The identification of an epigenetic fingerprint of diabetes in pregnancy linked to the metabolic health of the offspring might provide novel biomarkers for the identification of offspring most at risk, before the onset of metabolic dysfunction, for targeted monitoring and intervention. In this Personal View, we (1) highlight the scale of the problem of diabetes in pregnancy, (2) summarise evidence for the variation in offspring epigenetic profiles following exposure to diabetes in utero, and (3) outline potential future approaches to further understand the mechanisms by which exposure to maternal metabolic dysfunction in pregnancy is transmitted through generations.

    Original languageEnglish
    Pages (from-to)796-806
    Number of pages11
    JournalThe Lancet Diabetes and Endocrinology
    Volume7
    Issue number10
    Early online date22 May 2019
    DOIs
    Publication statusPublished - 1 Oct 2019

    Fingerprint

    Pregnancy in Diabetics
    Epigenomics
    Metabolic Diseases
    Maternal Exposure
    Pregnancy Complications
    Disease Susceptibility
    Dermatoglyphics
    Biomarkers
    Mothers
    Pregnancy
    Health

    Cite this

    Hjort, Line ; Novakovic , Boris ; Grunnet , Louise G ; Maple-Brown, Louise ; Damm, Peter ; Desoye, Gernot ; Saffery, Richard. / Diabetes in pregnancy and epigenetic mechanisms : how the first 9 months from conception might affect the child's epigenome and later risk of disease. In: The Lancet Diabetes and Endocrinology. 2019 ; Vol. 7, No. 10. pp. 796-806.
    @article{58e5e06a1c6640bb84c1e8a5ee4fd8c5,
    title = "Diabetes in pregnancy and epigenetic mechanisms: how the first 9 months from conception might affect the child's epigenome and later risk of disease",
    abstract = "Diabetes in pregnancy is not only associated with increased risk of pregnancy complications and subsequent maternal metabolic disease, but also increases the risk of long-term metabolic disease in the offspring. At the interface between genetic and environmental factors, epigenetic variation established in utero represents a plausible link between the in utero environment and later disease susceptibility. The identification of an epigenetic fingerprint of diabetes in pregnancy linked to the metabolic health of the offspring might provide novel biomarkers for the identification of offspring most at risk, before the onset of metabolic dysfunction, for targeted monitoring and intervention. In this Personal View, we (1) highlight the scale of the problem of diabetes in pregnancy, (2) summarise evidence for the variation in offspring epigenetic profiles following exposure to diabetes in utero, and (3) outline potential future approaches to further understand the mechanisms by which exposure to maternal metabolic dysfunction in pregnancy is transmitted through generations.",
    author = "Line Hjort and Boris Novakovic and Grunnet, {Louise G} and Louise Maple-Brown and Peter Damm and Gernot Desoye and Richard Saffery",
    year = "2019",
    month = "10",
    day = "1",
    doi = "10.1016/S2213-8587(19)30078-6",
    language = "English",
    volume = "7",
    pages = "796--806",
    journal = "The Lancet Diabetes and Endocrinology",
    issn = "2213-8587",
    publisher = "The Lancet Publishing Group",
    number = "10",

    }

    Diabetes in pregnancy and epigenetic mechanisms : how the first 9 months from conception might affect the child's epigenome and later risk of disease. / Hjort, Line; Novakovic , Boris; Grunnet , Louise G ; Maple-Brown, Louise; Damm, Peter; Desoye, Gernot ; Saffery, Richard.

    In: The Lancet Diabetes and Endocrinology, Vol. 7, No. 10, 01.10.2019, p. 796-806.

    Research output: Contribution to journalReview articleResearchpeer-review

    TY - JOUR

    T1 - Diabetes in pregnancy and epigenetic mechanisms

    T2 - how the first 9 months from conception might affect the child's epigenome and later risk of disease

    AU - Hjort, Line

    AU - Novakovic , Boris

    AU - Grunnet , Louise G

    AU - Maple-Brown, Louise

    AU - Damm, Peter

    AU - Desoye, Gernot

    AU - Saffery, Richard

    PY - 2019/10/1

    Y1 - 2019/10/1

    N2 - Diabetes in pregnancy is not only associated with increased risk of pregnancy complications and subsequent maternal metabolic disease, but also increases the risk of long-term metabolic disease in the offspring. At the interface between genetic and environmental factors, epigenetic variation established in utero represents a plausible link between the in utero environment and later disease susceptibility. The identification of an epigenetic fingerprint of diabetes in pregnancy linked to the metabolic health of the offspring might provide novel biomarkers for the identification of offspring most at risk, before the onset of metabolic dysfunction, for targeted monitoring and intervention. In this Personal View, we (1) highlight the scale of the problem of diabetes in pregnancy, (2) summarise evidence for the variation in offspring epigenetic profiles following exposure to diabetes in utero, and (3) outline potential future approaches to further understand the mechanisms by which exposure to maternal metabolic dysfunction in pregnancy is transmitted through generations.

    AB - Diabetes in pregnancy is not only associated with increased risk of pregnancy complications and subsequent maternal metabolic disease, but also increases the risk of long-term metabolic disease in the offspring. At the interface between genetic and environmental factors, epigenetic variation established in utero represents a plausible link between the in utero environment and later disease susceptibility. The identification of an epigenetic fingerprint of diabetes in pregnancy linked to the metabolic health of the offspring might provide novel biomarkers for the identification of offspring most at risk, before the onset of metabolic dysfunction, for targeted monitoring and intervention. In this Personal View, we (1) highlight the scale of the problem of diabetes in pregnancy, (2) summarise evidence for the variation in offspring epigenetic profiles following exposure to diabetes in utero, and (3) outline potential future approaches to further understand the mechanisms by which exposure to maternal metabolic dysfunction in pregnancy is transmitted through generations.

    UR - http://www.scopus.com/inward/record.url?scp=85072195647&partnerID=8YFLogxK

    U2 - 10.1016/S2213-8587(19)30078-6

    DO - 10.1016/S2213-8587(19)30078-6

    M3 - Review article

    VL - 7

    SP - 796

    EP - 806

    JO - The Lancet Diabetes and Endocrinology

    JF - The Lancet Diabetes and Endocrinology

    SN - 2213-8587

    IS - 10

    ER -